RxDoctor Payments Data

Aaron Klein, DO

Internal Medicine · Boca Raton, FLNPI 1790708261

Payments from drug & device makers

$981in general payments, 2019–2025

Across 37 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$238
  • Novo Nordisk$167
  • AstraZeneca$125
  • Novartis$105
  • Johnson & Johnson$89
  • Exact Sciences$57
  • plus $200 from 7 others

What the payments were for

  • Food & beverage$981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$190,689
Medicare patients
291
Services billed
2,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$86,382
MounjaroTirzepatide61$66,383
JardianceEmpagliflozin49$54,133
XareltoRivaroxaban43$47,918
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,262
EntrestoSacubitril/Valsartan17$10,460
Breo ElliptaFluticasone/Vilanterol17$8,883
VascepaIcosapent Ethyl17$7,949
FarxigaDapagliflozin Propanediol14$7,521
JanuviaSitagliptin Phosphate13$7,089
Rosuvastatin Calcium289$5,061
SynthroidLevothyroxine Sodium44$4,892
Midodrine Hcl47$4,444
Ezetimibe96$3,086
Memantine Hcl16$3,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$49$66,38361 claims
Boehringer IngelheimJardiance$28$54,13349 claims
Johnson & JohnsonXarelto$89$47,91843 claims
NovartisEntresto$105$10,46017 claims
AstraZenecaFarxiga$125$7,52114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →